Corrigendum to ‘efficacy and Safety of Paclitaxel Liposome Versus Paclitaxel in Combination with Carboplatin in the First-Line Chemotherapy for Ovarian Cancer: a Multicenter, Open-Label, Non-Inferiority, Randomized Controlled Trial’ [journal of the National Cancer Center 4 (2024) 135–141]